Relo Group, Inc. will acquire shares of ATIV Medical and make it a subsidiary. The purchase price is approximately 1,680 million yen (1,620 million yen for ATIV Medical common shares and an estimated 50\u201360 million yen for advisory fees, etc.). The post-acquisition voting rights ratio will be 90.0%. The acquisition decision date is 2026-10-20 and the execution date is scheduled for 2026-10-30. The aim is to create synergies with the overseas assignment support business. The impact on consolidated results is currently being examined.<\/p>\n","protected":false},"comment_status":"open","ping_status":"closed","template":"","meta":{"Ticker":"","DATE":"","longName":"","company_name_ja":"","fullTimeEmployees":0,"address":"","phone":"","website":"","industry":"","sector":"","regularMarketPrice":0,"financialCurrency":"","marketCap":0,"fiftyTwoWeekLow":0,"fiftyTwoWeekHigh":0,"epsTrailingTwelveMonths":0,"epsForward":0,"bookValue":0,"totalRevenue":0,"OperatingIncome":0,"operatingMargins":0,"NetIncome":0,"profitMargins":0,"ebitda":0,"trailingPE":0,"forwardPE":0,"priceToBook":0,"returnOnEquity":0,"recommendationMean":0,"recommendationKey":"","targetMeanPrice":0,"numberOfAnalystOpinions":0,"analyst_earnings_data":"","dividendRate":0,"dividendYield":0,"payoutRatio":0,"totalEsg":0,"environmentScore":0,"socialScore":0,"governanceScore":0,"title":"","providerPublishTime":"","link":"","longBusinessSummary":"","longBusinessSummary_ja":"","quarterly_revenue":0,"quarterly_net_income":0,"quarterly_operating_profit":0,"enterprise_value":0,"price_fetched_at":"","company_officer_1_name":"","company_officer_1_title":"","company_officer_2_name":"","company_officer_2_title":"","company_officer_3_name":"","company_officer_3_title":"","company_officer_4_name":"","company_officer_4_title":"","company_officer_5_name":"","company_officer_5_title":"","company_officers_update_time":"","get_dividend_history_year1":0,"get_dividend_history_year2":0,"get_dividend_history_year3":0,"get_dividend_history_year4":0,"get_dividend_history_year5":0,"get_dividend_history_year6":0,"get_dividend_history_year7":0,"get_dividend_history_year8":0,"get_dividend_history_year9":0,"get_dividend_history_year10":0,"site-sidebar-layout":"default","site-content-layout":"","ast-site-content-layout":"","site-content-style":"default","site-sidebar-style":"default","ast-global-header-display":"","ast-banner-title-visibility":"","ast-main-header-display":"","ast-hfb-above-header-display":"","ast-hfb-below-header-display":"","ast-hfb-mobile-header-display":"","site-post-title":"","ast-breadcrumbs-content":"","ast-featured-img":"","footer-sml-layout":"","theme-transparent-header-meta":"","adv-header-id-meta":"","stick-header-meta":"","header-above-stick-meta":"","header-main-stick-meta":"","header-below-stick-meta":"","astra-migrate-meta-layouts":"default","ast-page-background-enabled":"default","ast-page-background-meta":{"desktop":{"background-color":"var(--ast-global-color-5)","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""},"tablet":{"background-color":"","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""},"mobile":{"background-color":"","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""}},"ast-content-background-meta":{"desktop":{"background-color":"var(--ast-global-color-4)","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""},"tablet":{"background-color":"var(--ast-global-color-4)","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""},"mobile":{"background-color":"var(--ast-global-color-4)","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""}},"jir_stock_code":"8876","jir_company_name":"Relo Group, Inc.","jir_importance":"\u2605\u2605\u2605\u2605\u2606","jir_publication_date":"2026-10-20","jir_source_link":"https:\/\/japanir.jp\/wp-content\/uploads\/2026\/10\/8876-20261020-01.pdf","jir_short_summary":"Relo Group, Inc. will acquire shares of ATIV Medical and make it a subsidiary. The purchase price is approximately 1,680 million yen (1,620 million yen for ATIV Medical common shares and an estimated 50\u201360 million yen for advisory fees, etc.). The post-acquisition voting rights ratio will be 90.0%. The acquisition decision date is 2026-10-20 and the execution date is scheduled for 2026-10-30. The aim is to create synergies with the overseas assignment support business. The impact on consolidated results is currently being examined.","jir_summary":"### Transaction Overview\nRelo Group, Inc. announced a decision to acquire shares of ATIV Medical Pte. Ltd. and make it a subsidiary. The total acquisition amount is approximately 1,680 million yen (1,620 million yen for ATIV Medical common shares and an estimated 60 million yen for advisory fees, etc.). After the acquisition, the ownership will be 90.0%, and the number of voting rights will be 242,910,000. The decision date is 2026-10-20, and the planned execution date is 2026-10-30. ATIV Medical is a corporate group that provides healthcare services for Japanese expatriates and travelers in Southeast Asia.\n\n### Business Strategy and Impact\nThis transaction aims to strengthen the value chain of the overseas assignment support business and generate synergies, aligning with the Relo Group, Inc. vision to support Japanese companies' overseas expansion. By integrating ATIV Medical's management consulting services for medical institutions, the Company intends to improve the quality of local life support and accelerate global expansion. The impact on future consolidated financial results is under review, but it is judged to contribute to improved performance.","jir_financial_highlights":"Acquisition Price: 1,620 million yen (Unknown)\nAdvisory Fees, etc.: 60 million yen (Unknown)\nNumber of Shares Acquired: 242,910,000 shares (Unknown)","jir_category":"","jir_hashtags":"#ReloGroup, #Subsidiarization, #OverseasBusinessExpansion","jir_key_figures":"Number of Shares Acquired: 242,910,000 shares (Voting rights ratio after acquisition 90.0%)\nAcquisition Price: ATIV Medical common shares 1,620 million yen\nEstimated Total Cost: 1,680 million yen","jir_meta_title":"Relo Group, Inc. Decides to Make ATIV Medical a Subsidiary\uff5cOctober 2026","jir_meta_description":"Relo Group, Inc. will acquire shares of ATIV Medical and make it a subsidiary. The acquisition amount is approximately 1,680 million yen, and the post-acquisition voting rights ratio will be 90.0%. The move aims to create synergies in the overseas assignment support business.","jir_og_title":"Relo Group, Inc. Decides to Make ATIV Medical a Subsidiary\uff5cOctober 2026","jir_og_description":"Relo Group, Inc. will make ATIV Medical a subsidiary. The total acquisition amount is approximately 1,680 million yen, and the post-acquisition voting rights ratio will be 90.0%, strengthening the overseas assignment support business.","jir_og_image_url":"\/assets\/og\/company-general_ir.jpg","jir_chart_data_collection":"[]","ir_related_company":8782,"ir_release_date":"","ir_type":"","ir_is_new":false,"ir_document_url":"","jir_ir_type":"executive_change","footnotes":""},"sector":[],"importance":[],"class_list":["post-132875","ir_release","type-ir_release","status-publish","hentry"],"yoast_head":"\n